Pfizer, riding high on COVID windfall, eyes $5B play for Global Blood Therapeutics: WSJ Amgen takes BiTEs out of pipeline, dropping BCMA, PSMA assets in light of data and competition Teladoc rival Amwell scores CVS tie-up to launch retailer's virtual primary care service Troubled testmaker Talis Biomedical drops COVID plans, lays off 35% of remaining staff Amgen sketches expansion plan for Lumakras as key launch lags thanks to diagnosis bottleneck Eli Lilly hit by migraine drug launch slowdown and a Reyvow no-show, but rivals Biohaven, AbbVie post sales boost ‘A negative trial, not a failed trial’: Neurocrine axes in-licensed tremor program on phase 2 data Senate to vote Saturday on major healthcare deal that includes drug price reforms FDA turns away Acadia's Nuplazid—again—this time in Alzheimer’s disease psychosis FDA clears Viz.ai’s algorithm to spot internal bleeds in brain scans Merck plans to count coughs and months until gefapixant is back in FDA hands Pain drug stigma stops patients from getting meds but opioid side effects, fatalities muddy waters Sutter Health's rising expenses and rough investments yield a $457M net loss for Q2 2022 Featured Story | By Eric Sagonowsky Riding high on its COVID-19 windfall, Pfizer has been busy scouring the biopharma landscape for new assets to bring into the fold. Now, the drugmaker appears to have set its sights on Global Blood Therapeutics and its marketed sickle cell disease drug Oxbryta. read more |
| |
|---|
|
Top Stories By Nick Paul Taylor Amgen is bowing out of the congested BCMA race. With a who’s who of drug developers going after the multiple myeloma target, the big biotech has decided to stop work on its bispecific contender as part of a cull that also saw it pick between its two PSMA prospects. read more By Heather Landi Telehealth company Amwell is working with CVS Health to roll out the retail drugstore giant's new virtual primary care service. read more By Conor Hale The point-of-care testmaker Talis Biomedical is undergoing a second wave of layoffs this year after struggling to get its COVID-19 diagnostic off the ground. It will make another 35% reduction in its headcount and is walking away from COVID testing altogether, pivoting instead to screeners for sexually transmitted diseases. read more By Angus Liu In the lead up to Amgen's second-quarter earnings reveal, Wall Street analysts warned that the company's targeted lung cancer drug Lumakras might disappoint in the U.S. It turns out they were right. read more By Ben Adams As the dust settles around pharma’s second-quarter financial readouts, we check in on how the new and increasingly crowded migraine market is looking. read more By Nick Paul Taylor Two years after licensing the asset for $45 million upfront, Neurocrine Biosciences has pulled the plug on the development of NBI-827104 in essential tremor after the failure of a phase 2a clinical trial to make the case for further investment. read more By Robert King The Senate is expected to hold a vote this weekend on the Inflation Reduction Act, which includes major reforms to drug prices and extends ACA subsides by three years. read more By Zoey Becker A little over a year ago, Acadia's Nuplazid received an FDA complete response letter in the broad indication of dementia-related psychosis. Now, the agency rejected the med in a more specific use based on concerns over its data package. read more By Andrea Park Viz SDH, which aims to detect subdural hematomas in CT images of the brain, is lucky No. 7 on Viz.ai's list of FDA-cleared imaging analysis algorithms. read more By Annalee Armstrong Merck & Co. is going to be counting coughs and months until the P2X3 receptor antagonist medicine gefapixant is back before regulators. read more By Ben Adams Chronic pain can be an unbearable burden for many patients. And while there are pain medications out there to help, stigma and concerns over addiction and abuse are getting in the way of patient access. The findings are based on a survey of just under 2,400 people conducted by the U.S. Pain Foundation, which is backed by pain drug pharma companies like Eli Lilly, Johnson & Johnson and Salix. read more By Dave Muoio The new numbers cement what was already looking to be a tricky year for the California nonprofit system, which during the previous quarter had reported a $184 million net loss. read more Resources Sponsored by: Triangle Insights Group, LLC The TrialCard/Triangle Insights Group platform is uniquely positioned to support you as your asset progresses through the value chain, by integrating strategic commercialization and market access insights with comprehensive patient and provider support services. Sponsored by: Thermo Fisher Scientific See how integration of innovative genetic analysis techniques into drug development is driving biopharma & biotech companies ahead. Sponsored by: Catalent What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored by: Catalent Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent Carla Vozone discusses the significant trends in the OINDP segment including large molecules and novel indications, changes within CDMOs and various challenges facing the industry. Sponsored by: Catalent Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. |
